TY  - JOUR
AU  - Baertsch, Marc-Andrea
AU  - Fougereau, Mathilde
AU  - Hielscher, Thomas
AU  - Sauer, Sandra
AU  - Breitkreutz, Iris
AU  - Jordan, Karin
AU  - Müller-Tidow, Carsten
AU  - Goldschmidt, Hartmut
AU  - Raab, Marc-Steffen
AU  - Hillengass, Jens
AU  - Giesen, Nicola
TI  - Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
JO  - Cancers
VL  - 13
IS  - 18
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2021-02189
SP  - 4706 
PY  - 2021
N1  - #LA:A360#
AB  - Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2-13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57
KW  - lenalidomide maintenance (Other)
KW  - multiple myeloma (Other)
KW  - salvage autologous stem cell transplantation (Other)
KW  - salvage high-dose chemotherapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34572934
C2  - pmc:PMC8472377
DO  - DOI:10.3390/cancers13184706
UR  - https://inrepo02.dkfz.de/record/176949
ER  -